Effect of Sildenafil Citrate on the Male Sexual Experience Assessed with the Sexual Experience Questionnaire: A Multicenter, Double‐Blind, Placebo‐Controlled Trial with Open‐Label Extension
| Autor: | Li-Jung Tseng, James G. McMurray, Ira W. Klimberg, Vera J. Stecher, LeRoy Jones, Rebecca Padula |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Psychometrics medicine.drug_mechanism_of_action Phosphodiesterase Inhibitors Sildenafil Libido Sexual Behavior Vasodilator Agents Urology Endocrinology Diabetes and Metabolism Placebo-controlled study Piperazines Sildenafil Citrate law.invention Double blind chemistry.chemical_compound Endocrinology Patient satisfaction Double-Blind Method Erectile Dysfunction Randomized controlled trial law Surveys and Questionnaires Internal medicine Humans Medicine Sulfones Orgasm Gynecology business.industry Penile Erection Reproducibility of Results Middle Aged medicine.disease Psychiatry and Mental health Erectile dysfunction Reproductive Medicine chemistry Patient Satisfaction Purines Quality of Life Open label business Phosphodiesterase 5 inhibitor |
| Zdroj: | The Journal of Sexual Medicine. 5:1955-1964 |
| ISSN: | 1743-6095 |
| Popis: | The Sexual Experience Questionnaire (SEX-Q) enables quick and easy assessment of functional, emotional, and satisfaction-related aspects of the sexual experience in men with erectile dysfunction (ED).To assess correlations between improvement on the SEX-Q and outcomes on other validated questionnaires. METHODS. Men with ED (scoreor =25 on the Erectile Function domain of the International Index of Erectile Function [IIEF]) who had used less than or equal to six doses of any phosphodiesterase 5 inhibitor (none within 6 months) were randomized to 10 weeks of double-blind, placebo-controlled (DBPC) flexible-dose sildenafil citrate (50 or 100 mg, as needed), followed by 6 weeks of open-label (OL) sildenafil.SEX-Q, IIEF, Quality of Erection Questionnaire (QEQ), Self-Esteem and Relationship (SEAR) Questionnaire, Erection Hardness Score (EHS), successful intercourse attempts (SIAs), Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), and global efficacy questions (GEQs).Compared with the placebo group (N = 105), the sildenafil group (N = 104) at DBPC end of treatment (EOT) had significantly more improvement (P0.05) on all SEX-Q, IIEF (except the Sexual Desire domain), QEQ, and SEAR outcomes, more frequent SIAs and EHS 3 (hard enough for penetration but not completely hard) or EHS 4 (completely hard) erections (odds ratio [OR], 2.52 and 3.46, respectively), EHS 4 erections four times as often (OR, 6.41), more men satisfied with treatment (EDITS; OR, 2.6), approximately twice as many men with improved erections (GEQ1; OR, 5.8) and ability to have sexual intercourse (GEQ2; OR, 5.4), and GEQ3 scores that indicated better sex (P0.0001). SEX-Q score improvements correlated positively with all other outcomes. At OL EOT, most outcomes were60% (and approximately half wereor =80%) of the maximum positive result.SEX-Q change scores correlate with several other functional, emotional, and satisfaction-related outcomes in men treated with sildenafil for ED, allowing a simple and focused evaluation of the sexual experience. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text